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Summary
Background Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that 
convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical 
benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and 
efficacy of hIVIG in a randomised controlled trial.
Methods This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argentina, Australia, 
Denmark, Greece, Mexico, Spain, Thailand, UK, and the USA over five influenza seasons from 2013–14 to 2017–18. Adults 
(≥18 years of age) were admitted for hospital treatment with laboratory-confirmed influenza A or B infection and were 
randomly assigned (1:1) to receive standard care plus either a single 500-mL infusion of high-titre hIVIG (0·25 g/kg 
bodyweight, 24·75 g maximum; hIVIG group) or saline placebo (placebo group). Eligible patients had a National Early 
Warning score of 2 points or greater at the time of screening and their symptoms began no more than 7 days before 
randomisation. Pregnant and breastfeeding women were excluded, as well as any patients for whom the treatment would 
present a health risk. Separate randomisation schedules were generated for each participating clinical site using permuted 
block randomisation. Treatment assignments were obtained using a web-based application by the site pharmacist who 
then masked the solution for infusion. Patients and investigators were masked to study treatment. The primary endpoint 
was a six-category ordinal outcome of clinical status at day 7, ranging in severity from death to resumption of normal 
activities after discharge. The choice of day 7 was based on haemagglutination inhibition titres from a pilot study. It was 
analysed with a proportional odds model, using all six categories to estimate a common odds ratio (OR). An OR greater 
than 1 indicated that, for a given category, patients in the hIVIG group were more likely to be in a better category than 
those in the placebo group. Prespecified primary analyses for safety and efficacy were based on patients who received an 
infusion and for whom eligibility could be confirmed. This trial is registered with ClinicalTrials.gov, NCT02287467.
Findings 313 patients were enrolled in 34 sites between Dec 11, 2014, and May 28, 2018. We also used data from 16 patients 
enrolled at seven of the 34 sites during the pilot study between Jan 15, 2014, and April 10, 2014. 168 patients were 
randomly assigned to the hIVIG group and 161 to the placebo group. 21 patients were excluded (12 from the hIVIG group 
and 9 from the placebo group) because they did not receive an infusion or their eligibility could not be confirmed. Thus, 
308 were included in the primary analysis. hIVIG treatment produced a robust rise in haemagglutination inhibition 
titres against influenza A and smaller rises in influenza B titres. Based on the proportional odds model, the OR on day 7 
was 1·25 (95% CI 0·79–1·97; p=0·33). In subgroup analyses for the primary outcome, the OR in patients with influenza A 
was 0·94 (0·55–1·59) and was 3·19 (1·21–8·42) for those with influenza B (interaction p=0·023). Through 28 days of 
follow-up, 47 (30%) of 156 patients in the hIVIG group and in 45 (30%) of 152 patients in the placebo group had the 
composite safety outcome of death, a serious adverse event, or a grade 3 or 4 adverse event (hazard ratio [HR] 1·06, 95% CI 
0·70–1·60; p=0·79). Six (4%) patients in the hIVIG group and five (3%) in the placebo group died, but these deaths were 
not necessarily related to treatment.
Interpretation When administered alongside standard care (most commonly oseltamivir), hIVIG was not superior to 
placebo for adults hospitalised with influenza infection. By contrast with our prespecified subgroup hypothesis that 
hIVIG would result in more favourable responses in patients with influenza A than B, we found the opposite effect. 
The clinical benefit of hIVIG for patients with influenza B is supported by antibody affinity analyses, but confirmation 
is warranted.
Funding NIAID and NIH. Partial support was provided by the Medical Research Council (MRC_UU_12023/23) and 
the Danish National Research Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
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Introduction
About 650 000 people worldwide are estimated to die 
annually from respiratory complications of influenza,1 
and all-cause excess mortality could be affecting twice as 
many people.2 The main treatment for both outpatients 
and inpatients with influenza is with neuraminidase 
inhibitors, although therapy with cap-dependent endo-
nuclease inhibitors has also become available. However, 
considerable morbidity and mortality due to influenza 
still occur.3−5
During the 1918 influenza pandemic, which accounted 
for an estimated 50 million deaths,6 convalescent sera, 
plasma, or blood from individuals who recovered from 
influenza were given to patients with severe influenza-
induced pneumonia. These studies were largely 
predicated on the assumption that rapidly increasing 
titres of anti-influenza antibodies in acutely ill patients to 
protective convalescent concentrations might prevent 
clinical deterioration while the host’s immune system 
mounts its own endogenous response. A meta-analysis 
of these studies suggested that there was clinical benefit 
for those patients who were treated early in the course of 
disease.7 A subsequent systematic review of studies using 
convalescent plasma or serum also found evidence of 
clinical benefit, but the investigators reported that these 
studies, none of which were randomised trials, were of 
poor quality by contemporary standards and recom-
mended the evaluation of convalescent plasma in new, 
well designed clinical trials.8 Since that systematic review, 
a phase 2 trial of immune plasma plus standard care 
versus standard care alone was done in 98 patients with 
influenza A and B infection.9 The study did not show a 
clear benefit for immune plasma on the basis of the 
primary endpoint of normalisation of respiratory status 
at day 28, but favourable trends in several outcomes led 
to the design of a phase 3 trial of high-titre versus low-
titre anti-influenza plasma in patients with influenza A 
infection.10 However, in that trial, high-titre plasma did 
not confer significant clinical benefit over low-titre 
plasma.
A single randomised trial11 in severely ill patients with 
influenza A serotype H1N1 infection has also been 
done using anti-influenza hyperimmune intravenous 
immunoglobulin (hIVIG). Although not definitive, it 
suggested the need for further investigation on the 
basis of a subgroup analysis. In that trial, hIVIG was 
selected for its neutralising activity against the 
circulating strain A(H1N1)pdm09 and was compared 
with control intravenous immunoglobulin without 
neutralising activity. Overall, there was no evidence of a 
survival benefit of hIVIG in the 34 evaluable patients, 
who were in intensive care and on ventilator support. 
However, of the 22 patients who were treated within 
5 days of symptom onset, there were no deaths in the 
hIVIG group (n=12), but there were four in the control 
group (n=10). Conversely, for those patients treated 
later than 5 days after symptom onset, all patients in 
the hIVIG group died (n=5), but none did in the control 
group (n=7). The subgroup results for patients who 
were treated early led the investigators to conclude that 
intravenous immunoglobulin should be considered in 
future pandemics.
Considering the limitations of the two meta-analyses 
and the results of the two clinical trials, the hypothesis 
that treating ill patients with convalescent products from 
immune patients might have clinical benefit remains 
Research in context
Evidence before this study
We identified 9520 articles through searching PubMed with the 
terms “influenza”[All Fields]) AND (“immunotherapy”[All Fields]) 
AND “human”. The search was restricted to articles in English. We 
did not include any date restrictions; the earliest article we found 
was published in 1946. Although numerous case reports or small 
randomised or non-randomised studies of passive 
immunotherapy as either primary or adjunctive therapy have 
been published over the past century, to our knowledge, none 
have provided definitive evidence that there is a true clinical and 
virological benefit of passive immunotherapy for patients with 
severe influenza.
Added value of this study
In this international, randomised, double-blind, 
placebo-controlled trial we found that despite robust increases 
in haemagglutination inhibition titres for influenza A, and 
smaller magnitude increases in titres for influenza B, there was 
no clinical benefit observed in patients receiving a single 
infusion of weight-based anti-influenza hyperimmune 
intravenous immunoglobulin (hIVIG) either overall or for the 
predefined subgroup of interest with influenza A. Paradoxically, 
and contrary to our expectation, the addition of hIVIG to 
standard care for patients with influenza B had both a 
significant clinical benefit at day 7 and a significant virological 
benefit at day 3 compared with placebo. Anti-haemagglutinin 
antibody affinities were measured in the hIVIG lots 
administered, and much stronger antibody affinities were 
observed for B strains than for A strains.
Implications of all the available evidence
This trial provides strong evidence that passive immunotherapy 
as an adjunctive therapy for adults hospitalised with severe 
influenza A does not provide clinical benefit. Although the 
beneficial effect of hIVIG for patients with influenza B is 
supported by the antibody affinity analyses done on the lots of 
the study drug, confirmation of clinical and virological benefit is 
warranted in a further randomised controlled trial enrolling 
participants hospitalised with influenza B.
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unproven. To fill the gap in evidence on the efficacy of 
hIVIG and to potentially identify a treatment that could 
reduce morbidity and mortality in adults admitted to 
hospital with influenza infection, we did a double-blind 
randomised trial of clinical outcomes in patients treated 
with hIVIG plus standard care versus standard care 
alone.
Methods
Study design and participants
FLU-IVIG was an international, double-blind, placebo-
controlled trial designed and conducted by the 
International Network for Strategic Initiatives in Global 
HIV Trials (INSIGHT). We planned to include 45 major 
hospitals in Argentina, Australia, Denmark, Greece, 
Mexico, Spain, Thailand, UK, and the USA (appendix 
pp 3–4).
Adult patients (≥18 years of age) admitted for hospital 
treatment with influenza A (ie, A[H1N1]pdm09, H3N2) or 
B infection, locally determined by nucleic acid testing or by 
a rapid antigen test from a specimen obtained within 
2 days before randomisation, were eligible if they had a 
National Early Warning (NEW) score12 of 2 points or greater 
at the time of screening, had onset of any symptoms no 
more than 7 days before randomisation, and were expected 
to be hospitalised for more than 24 h. If the NEW score for 
eligibility was obtained before the day of randomisation, 
an updated NEW score was obtained as baseline at the 
time of randomisation, which did not need to be 2 points 
or greater. Women of childbearing age were included if 
they were willing to abstain from sexual intercourse or to 
use at least one form of contraception until day 28 of the 
study. Pregnant or breastfeeding women were excluded, as 
were patients who had received any other investigational 
drug therapy within the 30 days before the screening, had 
a history of allergic reaction to blood or plasma products, 
had IgA deficiency, or were at risk of thrombosis for any 
reason. Additional exclusion criteria were suspicion of 
infection with another type of influenza, inability to 
comply with the protocol, increased risk due to treatment 
as judged by the site study investigator, and extracorporeal 
membrane oxygenation at screening. All patients provided 
written informed consent. The trial was approved by the 
institutional review board or ethics committee for each 
clinical site. The protocol is available online. 
Randomisation and masking
Patients were randomly assigned (1:1) to receive 500 mL 
of either hIVIG solution (hIVIG group) or saline as 
placebo (placebo group), in addition to standard care. 
Randomisation was stratified by clinical site; a schedule 
for each site was prepared by the INSIGHT Statistical 
and Data Management Center at the University of 
Minnesota (Minneapolis, MN, USA) using permuted 
block randomisation. These schedules were maintained 
in secure files. After obtaining the treatment assignment 
using a web-based application, site pharmacists 
unmasked to treatment prepared the masked infusion 
bags of hIVIG or placebo. hIVIG solutions were slightly 
opaque. Thus, to ensure that the patient and clinical site 
staff were masked to the assigned treatment, the 
pharmacist placed a coloured sleeve over the 500 mL bag 
containing either the hIVIG or placebo.
Patients and investigators were masked to the study 
treatment administered. Apart from the site pharmacist, 
access to treatment assignment was restricted to the 
unmasked statisticians who prepared reports for the 
Data and Safety Monitoring Board. To assess the masking 
process, at the final follow-up visit on day 28, patients 
and a staff member primarily responsible for evaluating 
symptoms during follow-up were asked to guess which 
treatment was administered (appendix p 9).
Procedures
The hIVIG product was manufactured on an annual 
basis by Emergent BioSolutions (formerly Cangene 
Corporation; Winnipeg, MB, Canada) under contract to 
the National Institute of Allergy and Infectious Diseases, 
using high-titre anti-influenza plasma collected either 
from fractionated whole blood or by plasmapheresis 
from immune volunteers at sites in the USA and Canada. 
Donors and plasma units were selected on the basis of 
increased haemagglutination inhibition antibody titres 
against contemporary vaccine strains. Haemagglutination 
inhibition titres varied by hIVIG lot, and all lots were 
required to have substantial activity against contemporary 
circulating strains to be used (appendix p 12). The 
manufacturing methods and determination of neut-
ralising antibody titres in the individual IVIG lots did not 
vary over the course of the trial. After unmasking of the 
primary study results, additional characterisation of the 
antibody composition of each hIVIG lot administered 
during the study was done. This included measurement 
of the total antibody binding and antibody affinity to the 
HA0 protein (the native functionally intact form of 
haemagglutinin) for each of the influenza vaccine strains 
(appendix p 7).13
Before randomisation, demographics information and 
medical history were obtained, NEW score was assessed, 
use of antiviral medication was recorded, and targeted 
symptoms were ascertained. Nasopharyngeal swabs 
from patients were obtained at baseline and on day 3 for 
central determination of influenza serotypes and viral 
loads by RT-PCR (appendix p 6). Blood was obtained 
before infusion of the assigned solution and on 
days 1, 3, and 7 for measurement of haemagglutination 
inhibition titres.
On the basis of the favourable pharmacokinetics and 
haemagglutination inhibition titres measured during a 
pilot trial,14 hIVIG was given at a dose of 0·25 g/kg (up to 
a maximum of 24·75 g, corresponding to approximately 
100 kg actual bodyweight) dissolved in as much saline as 
needed to reach a total volume of 500 mL. A single 
infusion was given as soon as possible after 
For the trial protocol see 
https://insight.ccbr.umn.edu/i06/
index.php?study=i06&page=&me
nu=materials&submenu=protocol
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randomisation over a period of approximately 2 h. 302 
(98%) of patients were infused on the day of 
randomisation and six (2%) were infused on the day after 
randomisation.
Patients were followed up for 28 days after 
randomisation. Clinical data were collected on days 1–3, 
7, 14, and 28. These data included NEW score on days 1–3 
if the patient was hospitalised; targeted symptoms on 
days 3 and 7; nasopharyngeal swab on day 3; blood draws 
on days 1, 3, and 7; use of antiviral drugs; and adverse 
events throughout the entire follow-up period. Data were 
also collected on resolution of influenza symptoms. After 
infusion, the volume used and any subsequent adverse 
events were recorded.
Outcomes
An ordinal outcome with six mutually exclusive categories 
was used to describe the patient’s clinical status during 
follow-up. The six categories were: (1) death; (2) in 
intensive care; (3) hospitalised but requiring supplemental 
oxygen; (4) hospitalised and not requiring supplemental 
oxygen; (5) discharged but unable to resume normal 
activities; or (6) discharged with full resumption of normal 
activities. Day 7 was the timepoint chosen for assesment 
of the primary ordinal outcome on the basis of the results 
of the pilot study,14 which showed that hIVIG rapidly 
increases haemagglutination inhibition titres against 
influenza A virus well above protective concentrations 
induced by seasonal vaccination15−17 and that differences in 
haemagglutination inhibition titres between hIVIG and 
placebo solutions were greatest in the first few days after 
infusion of hIVIG.14 We also considered that measures of 
clinical status at subsequent timepoints could probably 
reflect the effect of comorbidities instead of influenza 
infection and potentially obscure any treatment 
differences. The properties of the novel ordinal outcome 
we used for the primary endpoint have already been 
described.18
Prespecified secondary outcomes to assess the clinical 
status of patients are detailed in the panel and the 
rationale for any modifications is detailed in the appendix 
(pp 42–45).
Serious adverse events and grade 3 and 4 adverse 
events19 were categorised according to codes used in the 
Medical Dictionary for Regulatory Activities (MedDRA), 
version 21.0.
Statistical analysis
The trial was designed to enrol 320 patients. This sample 
size provides 80% power to detect an odds ratio (OR) 
of 1·77 for hIVIG versus placebo at the 0·05 (2-sided) 
level of significance (appendix p 7).20 ORs greater than 
1·0 correspond to more favourable outcomes on hIVIG 
use compared with placebo.
An independent Data Safety Monitoring Board met 
five times during the trial to review interim safety and 
efficacy data (appendix p 13). The Board was asked to 
recommend early termination or modification of the 
trial only when there was clear and substantial evidence 
of a treatment difference. As a guideline, the Lan-DeMets 
spending function analogue of the O’Brien-Fleming 
boundaries was used to monitor the primary endpoint.21,22 
After approximately 70% of patients were enrolled, a 
futility analysis was provided to the Board by the 
unmasked statisticians. As a guideline, the Board was 
asked to consider futility if conditional power was less 
than 10%, given the observed data and the hypothesised 
treatment effect thereafter. These reviews by the Board 
did not lead to any modifications of the trial. No one 
except Board members and the unmasked statisticians 
had access to data summarising treatment comparisons.
From the outset of the FLU-IVIG trial, we planned to 
include the 16 patients who participated in the pilot study 
and met the eligibility criteria of FLU-IVIG in the 
primary analysis to reduce the cost of the trial 
(ie, enrolment costs and costs of preparing batches of 
hIVIG). The clinical outcomes of the 16 patients from the 
pilot study remained concealed until the results of the 
FLU-IVIG trial were unmasked. These patients were 
enrolled during the influenza season before the 
FLU-IVIG trial began.14 Data collected during the pilot 
study allowed all major outcomes to be determined.
Panel: Secondary outcomes 
Key outcomes
• Five-category ordinal outcome on day 3 (death, in intensive 
care, hospitalised with NEW score ≥3, hospitalised with 
NEW score <3, or discharged from hospital)
• The primary six-category ordinal outcome on day 3
• Favourable outcome at day 7, accounting for location of 
enrolment (ie, in intensive care at enrolment to general 
ward or discharge before day 7, or in general ward at 
enrolment to discharge before day 7)
Other outcomes
• The primary six-category outcome on days 14 and 28
• The primary six-category outcome on days 1 through 7
• Time to discharge
• Time to death
• Proportion of patients alive and discharged at day 28
• Change in nasopharyngeal viral load from baseline to day 3
• Change in haemagglutination inhibition titres from 
baseline to days 1, 3, and 7
• Proportion of patients dead or re-admitted to hospital 
after discharge
• Proportion of patients diagnosed on the day of 
randomisation or after with acute respiratory distress 
syndrome, acute renal failure, sepsis, pneumonia, 
enteritis, or bronchitis
• Proportion of patients alive and discharged at day 14
• Resumption of normal activities at day 14
NEW=National Early Warning.
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All analyses were done in patients who received an 
infusion and for whom eligibility could be confirmed. A 
proportional odds model was used to analyse the 
primary ordinal outcome at day 7.23 The proportional 
odds model uses all six categories and estimates a 
common OR over all possible clinical states of the 
ordinal outcome. We defined an OR greater than 1 for a 
given category as the odds of patients in the hIVIG 
group being in a better category at day 7 than patients 
in the placebo group. The model included a treatment 
indicator and covariates: (1) whether the patient was 
enrolled from the intensive care unit or general ward 
and whether they required oxygen; (2) geographical 
region (USA, South America, and Mexico; Europe and 
Australia; and Thailand); and (3) participation in the 
previous pilot study. In addition to the adjusted OR 
specified for the primary analysis, an unadjusted OR is 
cited for the primary ordinal outcome. Proportional 
odds models with the same covariates are summarised 
for secondary ordinal outcomes at day 3, day 14, and 
day 28 (appendix p 9). Separate ORs were also estimated 
for each dichotomised definition of improvement from 
the ordered categorical scale on day 7. A test for the 
proportional odds assumption from a model that 
allowed different slopes for the baseline covariates (a 
partial proportional odds model) was done. Multiple 
imputation was used to estimate the day-7 clinical 
status of patients for whom data on the primary 
outcome were partially missing (appendix p 8). The 
ordinal outcome was also assessed on each of the first 
7 days of follow-up. Generalised estimating equations 
were used to assess evidence of heterogeneity for these 
repeated assessments of the ordinal outcome. The 
interaction of study follow-up day and treatment was 
assessed and is referred to as an interaction p value. 
Sensitivity analyses are described in the appendix (p 8).
A major preplanned subgroup of interest were 
patients infected with influenza A serotypes A(H1N1) or 
A(H3N2) (appendix). We assumed that benefit would be 
greater for this subgroup, considering the substantial 
increase in haemagglutination inhibition titres that 
were seen after infusion with hIVIG in patients with 
A(H1N1) in the pilot study.14 Subgroups by influenza 
serotype and other measurements were defined at 
baseline by adding a cross-product term with treatment 
to the proportional odds model. Interaction p values are 
reported for this measure. Haemag glutination titres 
were analysed with geometric mean ratios and 95% CIs.
We used Kaplan-Meier curves and Cox regression to 
summarise safety outcomes, including a composite 
outcome of death, serious adverse events, or a grade 3 or 
4 adverse event. Logistic regression was used to 
summarise binary outcomes such as the components of 
the ordinal outcome and the sliding dichotomy 
favourable outcome,24 defined as alive and out of 
intensive care for those enrolled via the intensive care 
unit, and discharged alive for those enrolled via the 
general ward. Analysis of variance was used to 
summarise log-transformed haemagglutination inhibi-
tion titres against different reference viruses for each 
influenza type at days 0, 1, 3, and 7, and log-transformed 
viral load changes from baseline to day 3. Baseline titres 
and viral load were included as covariates in these 
analyses.
Statistical analyses were done with the SAS software, 
version 9.4. All p values reported are 2-sided. There was 
no adjustment for type 1 errors for the number of 
secondary endpoints and subgroups examined. Thus, 
they should be interpreted with caution.
This study is registered with ClinicalTrials.gov, 
NCT02287467.
Role of the funding source
Staff from the funder, the US National Institutes of 
Health, collaborated with members of the writing group 
on the study design, data collection plan, interpretation of 
data analyses, and the writing of the report. Access to raw 
data was restricted to AGB, DW, and NE. The 
corresponding author had final responsibility for the 
decision to submit for publication.
Results
329 patients were enrolled by 34 clinical sites over 
five influenza seasons, from 2013–14 to 2017–18. The 
Figure 1: FLU-IVIG trial profile
hIVIG=hyperimmune intravenous immunoglobulin.
160 assigned to hIVIG plus standard care
2 not infused
158 received their assigned intervention
8 included from 
    pilot study
166 in hIVIG plus standard care group
10 excluded for questionable 
 eligibility
4 had partially missing 
    primary outcome at day 7
156 included in the primary analysis
153 assigned to placebo plus standard care
2 not infused
151 received their assigned intervention
8 included from 
    pilot study
159 in placebo plus standard care group
7 excluded for questionable 
    eligibility
152 included in the primary analysis
313 eligible patients enrolled in FLU-IVIG trial 
 and randomly assigned to study groups
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329 patients included 313 enrolled directly in the 
FLU-IVIG trial between Dec 11, 2014, and May 28, 2018, 
and 16 patients from the pilot study enrolled between 
Jan 15, 2014, and April 10, 2014. 160 patients were assigned 
to the hIVIG group and 153 were assigned to the placebo 
group. Additionally, eight of the pilot-study patients 
received hIVIG and eight received placebo. Thus, 
168 recruited patients were included in the hIVIG group 
and 161 in the placebo group (figure 1). 21 patients were 
excluded (12 from the hIVIG group and nine from the 
placebo group) because they did not receive an infusion or 
their eligibility could not be confirmed. Of the 
308 remaining patients, the day-7 outcome was partially 
missing (discharge status was known) for four patients, 
but they were included in the analysis after data for them 
were imputed. Thus, the primary analysis included all 
308 patients (156 in the hIVIG group and 152 in the 
placebo group). All four patients with missing data were 
discharged before day 7; one withdrew consent after 
discharge and three could not be contacted. On the last 
day of follow-up, survival status was unknown for 
two patients, one in each treatment group.
Apart from the patients enrolled while in intensive 
care, more of whom were in the placebo group (23 [15%]) 
than the hIVIG group (12 [8%]), the two treatment groups 
were well balanced at baseline (table 1, appendix p 14). 
Median age was 57 years (IQR 45–68), and 168 (55%) of 
the 308 patients were women. 73 (24%) of all patients had 
an A(H1N1) infection, 137 (44%) had an A(H3N2) 
infection, and 84 (27%) had an influenza B infection. The 
proportion of patients with influenza A ranged from 
69 (64%) of 107 patients recruited between October, 2016, 
and September, 2017, to 14 (87%) of 16 patients recruited 
between December, 2013, and September, 2014, over the 
five seasons of enrolment (appendix p 27). The median 
number of days since symptom onset at entry 
was 3 (2–5) and median NEW score at enrolment was 
4 points (2–6). 256 (83%) of the 308 evaluable patients 
were randomly assigned to groups on the date of 
screening, and for these patients the baseline and 
eligibility NEW scores are identical. The remaining 
52 (17%) patients were screened on the day before 
randomisation, and for these patients the baseline NEW 
score could have decreased below 2 points. Treatment 
with neuraminidase inhibitors (oseltamivir) was 
prescribed to 148 (95%) patients in the hIVIG group and 
to 144 (95%) patients in the placebo group (appendix 
p 14). For 155 (50%) patients, oseltamivir was 
administered no later than 2 days after symptom onset.
The adjusted OR of hIVIG versus placebo for the 
primary endpoint was 1·25 (95% CI 0·79–1·97, p=0·33; 
table 2). The clinical status of patients on the basis of the 
primary ordinal outcome after data imputation is 
summarised in the appendix (p 29). The unadjusted OR 
was similar (1·26 [0·83–1·90], p=0·28), and there was no 
evidence that the proportional odds assumption was 
violated (p=0·79), as seen from the similarity of the 
five ORs (hIVIG vs placebo) estimated from the six 
categories of the ordinal outcome (table 2). Planned 
sensitivity analyses for the primary outcome showed 
consistent results, including the sensitivity analysis that 
excluded the pilot study participants (OR 1·31 [0·82–2·08], 
p=0·26; appendix p 17).
The OR for the primary ordinal outcome was determined 
for patients divided into subgroups according to 
characteristics at study entry (appendix pp 31–32). Findings 
for most subgroups, including duration of symptoms, 
ward of admission, use of oxygen at enrolment, and timing 
of antiviral use, were consistent with the overall findings. 
However, contrary to our preplanned hypothesis, a more 
hIVIG group 
(n=156)
Placebo group 
(n=152)
Age (years)
<40 35 (22%) 19 (13%)
40–59 57 (37%) 62 (41%)
≥60 64 (41%) 71 (47%)
Median (IQR) 55 (41–68) 57 (48–68)
Sex
Male 76 (49%) 64 (42%)
Female 80 (51%) 88 (58%)
Race
Asian 33 (21%) 36 (24%)
Black 27 (17%) 30 (20%)
White and other 96 (62%) 86 (57%)
Clinical status at enrolment
In intensive care 12 (8%) 23 (15%)
Hospitalised, requiring supplemental 
oxygen
68 (44%) 59 (39%)
Hospitalised, not requiring 
supplemental oxygen
76 (49%) 70 (46%)
Influenza serotype
A/H1N1 34 (22%) 39 (26%)
A/H3N2 72 (46%) 65 (43%)
A/subtype unknown 8 (5%) 6 (4%)
B/Victoria 6 (4%) 7 (5%)
B/Yamagata 34 (22%) 30 (20%)
B/lineage unknown 2 (1%) 5 (3%)
Days since symptom onset
≤3 85 (54%) 74 (49%)
4 27 (17%) 34 (22%)
≥5 44 (28%) 44 (29%)
Median (IQR) 3 (2–5) 4 (2–5)
NEW score
<2 19 (12%) 21 (14%)
2–3 55 (35%) 46 (30%)
4–5 38 (24%) 40 (26%)
≥6 44 (28%) 45 (30%)
Median (IQR) 4 (2–6) 4 (2–6)
Data are n (%) or median (IQR). Percentages might not add up because of 
rounding. NEW=National Early Warning.
Table 1: Baseline characteristics of the patients
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favourable outcome for the hIVIG group than for the 
placebo group was seen in patients with influenza B 
infection (OR 3·19 [95% CI 1·21–8·42]) compared with 
those with influenza A infection (0·94 [0·55–1·59]; 
interaction p=0·023; figure 2). Other prespecified clinical 
outcomes followed a similar pattern to the primary 
hIVIG group (n=156) Placebo group (n=152) OR or HR (95% CI) p value
Primary outcome
Ordinal outcome on day 7 ·· ·· 1·25 (0·79–1·97) 0·33
Binary components of the primary outcome
Categories 1–5 (vs 6; ie, alive vs dead) 153 (98%) 150 (99%) 0·66 (0·11–4·14) 0·66
Categories 1–4 (vs 5–6) 147 (94%) 139 (91%) 1·20 (0·44–3·26) 0·72
Categories 1–3 (vs 4–6) 132 (85%) 123 (81%) 1·17 (0·59–2·31) 0·65
Categories 1–2 (vs 3–6; ie, discharged vs hospitalised) 124 (79%) 111 (73%) 1·33 (0·72–2·44) 0·36
Categories 1 (vs 2–6) 68 (44%) 60 (40%) 1·29 (0·72–2·31) 0·39
Secondary outcomes
Primary ordinal outcome on day 3 ·· ·· 0·87 (0·57–1·33) 0·52
Primary ordinal outcome on day 14 ·· ·· 1·17 (0·70–1·95) 0·55
Primary ordinal outcome on day 28 ·· ·· 0·90 (0·50–1·62) 0·73
Ordinal five-category outcome on day 3 ·· ·· 0·95 (0·61–1·48) 0·84
Favourable sliding dichotomy outcome at day 7 128 (82%) 115 (76%) 1·49 (0·81–2·74) 0·20
Alive and discharged on day 28 140/155 (90%) 137/151 (91%) 0·87 (0·38–1·98) 0·74
Time to discharge through day 7 119 (76%) 110 (72%) 1·11 (0·85–1·45) 0·44
Viral load below the lower level of detection at day 3* 22/137 (16%) 28/137 (20%) 0·61 (0·31–1·20) 0·15
Data are n (%) or n/N (%), unless otherwise indicated. Percentages might not add up because of rounding. ORs are adjusted for baseline clinical status, region, and 
participation in the pilot study. A HR is reported only for the time-to-discharge outcome, with worst rank for death and stratification by the same baseline characteristics. 
The categories of the primary outcome are: (1) discharged with full resumption of normal activities; (2) discharged but unable to resume normal activities; (3) hospitalised, 
not requiring supplemental oxygen; (4) hospitalised but requiring supplemental oxygen; (5) in intensive care; and (6) dead. Evaluable participants for the ordinal outcome on 
day 3 were 155 in the hIVIG group and 152 in the placebo group. For the ordinal outcome on day 14, the evaluable patients were 152 in the hIVIG troup and the 151 in the 
placebo group. For the ordinal outcome on day 28, the evaluable patients were 151 in the hIVIG group and 150 in the placebo group. For the five-category outcome, there 
were 155 evaluable patients in the hIVIG group and 152 in the placebo group. HR=hazard ratio. NEW=National Early Warning. OR=odds ratio.*Adjusted for baseline viral RNA, 
geographical region, and influenza subtype. Excludes participants with undetectable viral RNA at baseline and counts deaths before day 3 as detectable.
Table 2: Outcomes summary
Figure 2: Proportional distribution of primary endpoint categories at day 7 of follow-up for patients infected with influenza A and B
(A) Proportions have been calculated from day-7 data for 111 patients in the hIVIG group and 110 in the placebo group. The OR estimate includes imputed data for 
three additional patients in the hIVIG group (n=114); these patients were discharged before day 7 and the imputation was on whether normal activities had been 
resumed. (B) Proportions have been calculated from day-7 data for 41 patients in the hIVIG and in the 42 placebo group. The OR estimate includes imputed data for 
one additional patient in the hIVIG group (n=42); this patient was discharged before day 7 and the imputation was on whether normal activities had been resumed. 
hIVIG=hyperimmune intravenous immunoglobulin. ICU=intensive care unit. OR=odds ratio.
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endpoint in showing no benefit of hIVIG compared with 
placebo in patients with influenza A infection, but evidence 
of benefit of hIVIG for those with influenza B infection 
(appendix pp 21–22). Planned sensitivity analyses for the 
primary outcome gave consistent results for both the 
influenza A and B subgroups (appendix p 23). Furthermore, 
when the primary endpoint was assessed on each of the 
first 7 days of follow-up with recorded data, all but two of 
Figure 3: Haemagglutination inhibition titres by reference virus and treatment group
Patients infected with influenza A(H1N1) with (A) A/California/07/2009 or (B) A/Michigan/45/2015 used as the reference virus for analysis. Patients infected with 
influenza A(H3N2) with (C) A/Hong Kong/4801/2014 or (D) A/Switzerland/2013/50/2012 used as the reference virus for analysis. Patients infected with influenza 
B with (E) B/Brisbane/60/2008 or (F) B/Phuket/3073/2013 used as the reference virus for analysis. hIVIG=hyperimmune intravenous immunoglobulin.
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the ORs for patients with influenza A infection were less 
than 1·0, and those greater than 1·0 were both 1·06 on 
days 5 and 6. ORs on days 1 and 2 were significantly less 
than 1·0, favouring the placebo group (interaction p=0·99 
for assessing the heterogeneity of the ORs over days 1–7; 
appendix p 24). For patients with influenza B infection, all 
ORs were greater than 1·0, particularly those on 
days 3–7, which were significant. The largest OR was on 
day 5 (OR 12·4 [4·1 to 37·6], interaction p=0·10; 
appendix p 25).
The lack of efficacy of hIVIG measured by the primary 
endpoint for patients with influenza A was evident for 
both serotypes (A[H1N1] OR 0·61 [95% CI 0·21–1·78], 
A[H3N2] 0·79 [0·41–1·54]; appendix p 31). Conversely, 
treatment differences for the two influenza B lineages 
both favoured hIVIG. The OR for those patients with the 
major Yamagata lineage was 4·37 (1·3–14·7). For those 
with the minor Victoria lineage, the OR could not be 
determined, but all six patients randomly assigned to 
receive hIVIG were discharged at day 7, whereas only 
four of the 7 assigned to placebo had been discharged.
In patients with A(H1N1)pdm09 infection, haemag-
glutination inhibition titres for A/California/07/2009/
A(H1N1) and A/Michigan/45/2015, the two reference 
viruses we considered, increased in the hIVIG group on 
day 1 (p<0·0001 for California, p<0·0001 for Michigan) and 
remained significantly higher than titres in the placebo 
group at day 3 (p=0·0001 for California, p<0·0001 for 
Michigan; figure 3, appendix p 15). By day 7, patients in the 
placebo group had developed natural immune responses 
and the treatment differences were no longer significant 
(p=0·18 for A/California/07/2009/A[H1N1], p=0·10 for 
A/Michigan/45/2015). A similar pattern of a smaller 
treatment difference in titres at day 7 (p=0·13) compared 
with day 1 (p<0·0001) and 3 (p<0·0001) was evident for 
patients infected with A(H3N2) for the reference virus 
A/Hong Kong/4801/2014. For those infected with 
A/Switzerland/2013/50/2012, titres in the hIVIG group 
differed from the placebo group at day 1 (p=0·0001) but not 
afterwards (p=0·65 for day 3, p=0·25 for day 7).
For patients with influenza B infection, haemag-
glutination inhibition titres were measured for both the 
Figure 4: Antibody affinity of hIVIG to properly folded haemagglutinin of seasonal influenza vaccine strains in SPR analysis
Sequential SPR analysis of human hIVIG was done against properly folded homologous haemagglutinin from the H1N1pdm09, H3N2, and B influenza vaccine strains 
for each lot of hIVIG used. 50-fold, 100-fold, and 200-fold dilutions of individual hIVIG lots were evaluated. Antibody off-rate constants that describe the fraction of 
antibody-antigen complexes decaying per second were determined directly from the hIVIG interaction with each of the three haemagglutinin proteins using SPR in 
the dissociation phase (appendix p 7). Slower dissociation kinetics (off-rate) of antigen-antibody complex means higher antibody affinity. hIVIG=hyperimmune 
intravenous immunoglobulin. SPR=surface plasmon resonance.
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B/Brisbane/60/2008 and B/Phuket/3073/2013 serotypes 
(figure 3). The increase in titres over time for both the 
hIVIG and placebo groups was lower than for patients 
with influenza A. Treatment differences were not 
significant at days 1, 3, or 7 for B/Brisbane/60/2008 
(p values ranged from 0·13 to 0·33). For the 
B/Phuket/3073/2013 reference virus, titres in the hIVIG 
group were significantly higher than in the placebo 
group at days 1 (p=0·0004) and 3 (p=0·021), but not day 7 
(p=0·78).
The greater increase in haemagglutination inhibition 
titres with hIVIG against influenza A compared with 
influenza B is consistent with the lot analysis 
(appendix p 12). However, in a post-trial exploratory 
laboratory analysis, the antibody kinetics showed an 
approximately tenfold (range 5·3–17·7) higher antibody 
affinity (slower antigen-antibody complex dissociation 
rates) against the haemagglutinin of influenza B strains 
than that of either the H1 or H3 vaccine strain for all 
hIVIG lots (figure 4). In most lots, anti-influenza B 
haemagglutinin-binding antibodies were higher than 
anti-H1 or anti-H3 antibodies, but not by much 
(appendix p 28).
Shed viral load decreased by 1·99 log10 copies per mL in 
the hIVIG group and 2·32 log10 copies per mL in the 
placebo group during the first 3 days (p=0·49; figure 5, 
appendix p 16). At day 3, 22 (16%) of the 137 assessed 
patients in the hIVIG group and 28 (20%) of 137 assessed 
patients in the placebo group had no detectable virus 
(p=0·15; table 2). For the subgroup of patients who received 
antiviral drugs within 2 days of symptom onset, viral load 
decreased by 2·75 log10 copies per mL in the hIVIG group 
and 3·08 log10 copies per mL in the placebo group (p=0·74).
ORs of the ordinal outcome on each of the first 7 days 
of follow-up (data as observed with no imputation; 
appendix p 18) showed that outcomes on days 1–3 in the 
placebo group were more favourable, but not significant, 
than in the hIVIG group. The OR on day 5 was 
1·75 (95% CI 1·13–2·70, p=0·013). The interaction 
p value for the test for heterogeneity of the OR over 
days 1 to 7 was 0·39.
Similar to the primary outcome, differences between 
the hIVIG and placebo group in other clinical outcomes 
were not significant (table 2).
hIVIG group 
(n=156)
Placebo group 
(n=152)
Event
Death 6 (4%) 5 (3%)
Any serious adverse event 25 (16%) 26 (17%)
Any grade 4 adverse event 22 (14%) 17 (11%)
Any grade 3 adverse event 31 (20%) 34 (22%)
Composite outcomes ranked by severity
Death 6 (4%) 5 (3%)
Death or serious adverse event 25 (16%) 26 (17%)
Death, serious adverse event, 
or grade 4 adverse event
29 (19%) 29 (19%)
Death, serious adverse event, 
or grade 3 or 4 adverse event*
47 (30%) 45 (30%)
Adverse events are graded according to the DAIDS toxicity table. DAIDS=Division 
of Acquired Immunodeficiency Syndrome. HR=hazard ratio. *HR 1·06, 95% CI 
0·70–1·60, p=0·79.
Table 3: Death and adverse events
Figure 5: Change in overall and serotype-specific nasopharyngeal viral load
Analyses only include participants with detectable viral load at baseline and are adjusted for baseline viral load and geographical region. The overall analysis was also 
adjusted for influenza subtype. *Excludes five participants with unknown serotype. †Excludes three participants with unknown lineage.
Proportion 
of patients 
per group
hIVIG Placebo
Overall
Influenza type
Influenza A
Influenza B
Influenza A serotype*
A(H1N1)
A(H3N2)
Influenza B lineage†
Victoria
Yamagata
 270 (88%)
 195 (63%)
 75 (24%)
 64 (21%)
 127 (41%)
 13 (4%)
 59 (19%)
5·02 (1·72)
4·82 (1·70)
5·53 (1·66)
4·54 (1·66)
4·98 (1·70)
5·51 (1·40)
5·70 (1·58)
−1·99
−1·95
−2·09
−1·74
−2·01
−2·19
−2·26
 0·14 (–0·26 to 0·53, 0·49)
 0·50 (0·08 to 0·93, 0·021)
 −0·85 (–1·70 to 0·0, 0·053)
 0·71 (–0·08 to 1·51, 0·084)
 0·50 (–0·02 to 1·02, 0·061)
 0·62 (–1·37 to 2·61, 0·56)
 −1·29 (–2·21 to –0·37, 0·0083)
−2·32
−2·62
–1·54
−2·55
−2·67
–2·28
−1·46
0·0052
0·78
0·24
Mean change
(log10 copies per mL)
Estimated difference 
(95% CI, p value)
p value for
interaction
Mean baseline
nasopharyngeal
viral load
(log10 copies 
per mL [SD])
Favours hIVIG Favours placebo
0–1 0·5–1·75 1 1·5
Articles
www.thelancet.com/respiratory   Vol 7   November 2019 961
Through 28 days of follow-up, a similar number of 
patients administered hIVIG and placebo died (six [4%] in 
the hIVIG group and five [3%] in the placebo group), had 
serious adverse events (25 [16%] in the hIVIG group, 
26 [17%] in the placebo group), and had grade 3 or 4 adverse 
events (45 [29%] in the hIVIG group and 40 [26%] in the 
placebo group; table 3, appendix pp 19–20). The 
composite outcome of death, serious adverse events, or 
grade 3 or 4 events was seen in 47 (30%) patients in the 
hIVIG group and in 45 (30%) patients in the placebo 
group (hazard ratio [HR] 1·06 [95% CI 0·70–1·60], 
p=0·79; table 3, appendix p 30). Viral load and safety 
outcome treatment differences followed a pattern similar 
to the primary endpoint for patients with influenza A 
and B. In patients with influenza A, the decline in viral 
load from baseline to day 3 was actually greater for the 
placebo group than the hIVIG group (difference 0·50; 
p=0·021), whereas for those with influenza B the decline 
in viral load was greater for the hIVIG group than for the 
placebo group (difference –0·85, p=0·053, p=0·0052 for 
interaction between treatment group and influenza 
serotype; figure 5, appendix p 26).
In patients with influenza A, the composite of death, 
serious adverse events, or grade 3 or 4 events occurred 
for 40 (35%) patients administered hIVIG and 29 (26%) 
patients administered placebo (HR 1·49 [95% CI 
0·91–2·42], p=0·11; appendix p 33). For those with 
influenza B infection, this composite occurred for 
seven (17%) patients in the hIVIG group and 
16 (38%) patients in the placebo group (0·38 [0·15–0·97], 
p=0·043 interaction p=0·010; appendix p 34).
Discussion
In this randomised controlled trial assessing 
immunotherapy as a potential therapeutic adjunct in 
patients with severe influenza, a significant treatment 
benefit of hIVIG plus standard care (oseltamivir) 
compared with placebo plus standard care was not found 
either overall or for the predefined subgroup of interest 
with influenza A infection (224 [73%] of 308 trial 
participants). The findings for the primary clinical 
outcome and several secondary clinical outcomes were 
matched by the inability of hIVIG treatment to induce a 
larger reduction in influenza A viral load in the upper 
respiratory tract than placebo. These findings for patients 
with influenza A are consistent with the results of a 
contemporaneous randomised trial (IRC005) of high-
titre anti-influenza plasma done in 140 patients with 
influenza A infection.10 In that trial, which enrolled a 
moderately sicker cohort than ours, the same primary 
endpoint was used and the OR (high-titre vs low-titre 
plasma) for a favourable outcome on day 7 was 
1·22 (95% CI 0·65–2·29). Taken together, the findings 
from the subgroup of patients with influenza A in our 
trial of hIVIG and the IRC005 trial provide no support 
for the use of immunotherapy to treat patients with 
severe influenza A.
Unlike the trial of high-titre anti-influenza plasma that 
only enrolled patients with influenza A, in our trial of 
hIVIG 84 (27%) patients had influenza B infection. 
Contrary to what was hypothesised on the basis of 
conventional haemagglutination inhibition titres, the 
addition of hIVIG to standard care did result in both a 
demonstrable clinical and a virological benefit in patients 
with influenza B. The OR in favour of a clinical benefit 
on the primary outcome for hIVIG use in patients with 
influenza B was 3·19 (95% CI 1·21–8·42). Secondary 
clinical and viral load outcomes were consistent with the 
primary outcome results for this subgroup. Particularly, 
the effect of hIVIG treatment on deaths and adverse 
events, which might reflect the underlying medical 
condition of patients better than adverse effects of 
treatment, was also greater in patients with influenza B 
than those with influenza A infection.
The rationale for choosing hIVIG as a potential 
therapeutic was based on the known course of the 
development of haemagglutination inhibition antibodies 
during natural infection that appears to correlate 
temporally with clinical recovery. Infusion of an anti-
influenza IVIG product produces a substantial rise in 
haemagglutination inhibition titres against A(H1N1) 
and A(H3N2) at least 3–4 days sooner than those induced 
by natural infection itself.14 By contrast, acute infection 
with influenza B (or after seasonal vaccination) produces 
a haemagglutination inhibition response against B virus 
that typically is much more muted when tested by 
conventional means, and the corresponding increase in 
anti-influenza B titres after hIVIG infusion is generally 
smaller. For this reason, we launched the hIVIG trial 
expecting to observe a greater treatment effect against 
the two major influenza A subtypes.
In preclinical studies of A(H5N1) infection in ferrets, 
increasing IVIG dose was associated with improved 
efficacy.25 Measurement of post-infusion haema gglutin-
ation inhibition titres against contem poraneously 
circulating influenza A strains in our trial did indeed 
suggest that the expected boost in titres was achieved in 
recipients of hIVIG. Accordingly, we anticipated that this 
measurably greater increase in haemagglutination 
inhibition titres against influenza A than against B might 
yield better efficacy in patients with influenza A infection. 
Yet this strategy to jumpstart the humoral response to 
acute infection by several days translated into more rapid 
clinical recovery and more rapid virological decline only 
in patients with influenza B, whose post-infusion titres 
increased little beyond baseline. As such, the conventional 
haemagglutination inhibition titres resulting from 
administration of hIVIG appear to have been poor 
predictors of both clinical and virological efficacy in our 
trial.
These results raise at least two obvious questions: 
(1) whether conventional haemagglutination inhibition 
antibody titres, despite their longstanding use as 
predictors of post-vaccination efficacy against both 
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influenza A and B,15,26 are truly an appropriate surrogate 
for an effective humoral response in therapeutic studies 
against influenza A, and hence whether better markers of 
antibody-mediated activity might exist that should be 
substituted, and (2) whether the overall host immune 
response to infection with influenza B might differ in 
some fundamental way from that against influenza A. It is 
known, for example, that acute influenza infection is also 
associated with pronounced impairment of the cellular 
immune response, including defective T-cell responses 
and a sometimes lethal unbridling of the proinflammatory 
cytokine cascade.27,28 It is possible that the two major types 
of influenza virus interact differentially with the immune 
system and that, for example, the neutralising activity of 
virus-specific antibodies is more important in the host 
response to B virus infection than to infection with 
virus A. Alternatively, the immunomodulatory effects29 of 
the Fc portion of IVIG itself might behave differently in 
patients with either of these two types of influenza. It 
might also be conjectured that the generally greater 
antiviral potency of oseltamivir against influenza A 
subtypes than against influenza B might somehow have 
overshadowed the potential additive beneficial effects of 
the immunotherapy in the subset of patients with 
influenza A infection. However, arguing strongly against 
this possibility are the observations that (1) the 
improvement in viral titres over time in the influenza A 
subgroup was, in fact, worse than in the influenza B 
subgroup, and (2) the absence of benefit in the influenza A 
subgroup was no different in those for whom antiviral 
treatment was started early (ie, within 2 days of symptom 
onset) than in those in whom treatment was delayed.
Rather, perhaps a more probable explanation for this 
difference might be found in the antibody kinetic 
analyses of hIVIG lots after unmasking of the primary 
data. Striking differences between the affinities of anti-A 
and anti-B antibodies within the hIVIG lots were found. 
Unlike conventional haemagglutination inhibition 
testing, these analyses showed that the antibody avidity 
against influenza B was often up to tenfold higher than it 
was against either subtype of influenza A. A study30 
showed that higher anti-haemagglutinin antibody affinity 
provided better control of viral load in nasal washes and 
weight loss in vaccinated ferrets after challenge with 
wild-type H7N7 or H7N9 influenza virus.30 Although the 
mechanism for these avidity differences in human 
plasma is unknown, it is clear that the role of antibody 
affinity and other antibody effector functions need to be 
carefully evaluated to assess their importance in 
providing protection against severe disease due to 
influenza A and influenza B.
A limitation of our results is that the subgroup with 
influenza B included only 84 patients (27% of all 
participants in the trial). Thus, our estimates of efficacy 
have wide CIs. The consistent findings for this 
subgroup across other clinical outcomes and viral load 
argue for further exploration of this finding. Another 
limitation is the fact that 17 patients from one site had 
to be excluded because their eligibility could not be 
confirmed. In the sensitivity analyses, their exclusion 
had little impact on estimated ORs for the primary 
endpoint, but did reduce our power slightly. Finally, we 
note that our target population of patients hospitalised 
with influenza included only 35 (11%) of patients in 
intensive care at the time of enrolment and about half 
had NEW scores less than or equal to 3 points. Thus, 
we are not able to generalise our findings to severely ill 
patients. However, subgroup analyses according to 
NEW score, location of enrolment, use of oxygen at 
entry, and duration of symptoms at the time of 
enrolment did not identify consistent trends. Taken 
together with the lack of overall benefit in severely ill 
patients in the two plasma trials9,10 and the Hong Kong 
trial of hIVIG,11 the absence of benefit of immunotherapy 
for patients with influenza A might apply to a broader 
population than we studied.
Of note, the trial’s ability to assess the effect of hIVIG 
on mortality would have required a much larger sample 
size than we were able to enrol.18 Instead, a novel ordinal 
primary outcome was defined for a trial with a feasible 
sample size, and several secondary clinical outcomes 
were defined to further characterise the possible benefit 
of hIVIG compared with placebo. An advantage of the 
primary outcome used compared with mortality, 
including improved power, is that it assesses both 
improvement and deterioration in health status.18
In summary, on the basis of our results and the 
two plasma trials,9,10 hIVIG and plasma are not 
recommended for patients hospitalised with influenza A. 
By contrast, the beneficial clinical and viral load results of 
hIVIG consistently seen in patients with influenza B 
warrant further investigation at both the laboratory and 
clinical levels.
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